Cargando…

Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis

BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prost...

Descripción completa

Detalles Bibliográficos
Autores principales: Breidenbach, Clara, Roth, Rebecca, Ansmann, Lena, Wesselmann, Simone, Dieng, Sebastian, Carl, Ernst‐Günther, Feick, Günter, Oesterle, Alisa, Bach, Peter, Beyer, Burkhard, Borowitz, Rainer, Erdmann, Jörg, Kunath, Frank, Oostdam, Simba‐Joshua, Tsaur, Igor, Zengerling, Friedemann, Kowalski, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286449/
https://www.ncbi.nlm.nih.gov/pubmed/32233081
http://dx.doi.org/10.1002/cam4.2999
_version_ 1783544878337097728
author Breidenbach, Clara
Roth, Rebecca
Ansmann, Lena
Wesselmann, Simone
Dieng, Sebastian
Carl, Ernst‐Günther
Feick, Günter
Oesterle, Alisa
Bach, Peter
Beyer, Burkhard
Borowitz, Rainer
Erdmann, Jörg
Kunath, Frank
Oostdam, Simba‐Joshua
Tsaur, Igor
Zengerling, Friedemann
Kowalski, Christoph
author_facet Breidenbach, Clara
Roth, Rebecca
Ansmann, Lena
Wesselmann, Simone
Dieng, Sebastian
Carl, Ernst‐Günther
Feick, Günter
Oesterle, Alisa
Bach, Peter
Beyer, Burkhard
Borowitz, Rainer
Erdmann, Jörg
Kunath, Frank
Oostdam, Simba‐Joshua
Tsaur, Igor
Zengerling, Friedemann
Kowalski, Christoph
author_sort Breidenbach, Clara
collection PubMed
description BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). METHODS: Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. RESULTS: Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of comorbidities (1‐2 vs 0, OR = 1.27; 95%‐CI = 1.00‐1.60; P=.048), disease staging (localized high‐risk vs localized intermediate risk, OR = 1.41; 95%‐CI = 1.14‐1.74; P < .001), receiving androgen deprivation therapy before study inclusion (OR = 0.19; 95%‐CI = 0.10‐0.34; P < .001), and hospital teaching status (university vs academic, OR = 0.09; 95%‐CI = 0.02‐0.55; P = .009). Model 2 additionally includes information on treatment after study inclusion and shows that after inclusion, patients who receive primary radiotherapy (OR = 0.05; 95%‐CI = 0.03‐0.10; P < .001) or undergo active surveillance/watchful waiting (OR = 0.06; 95%‐CI = 0.02‐0.15; P < .001) are less likely to utilize POS than patients who undergo radical prostatectomy. Disease staging (localized high‐risk vs localized intermediate risk, OR = 1.31; 95%‐CI = 1.05‐1.62; P = .02) and teaching status (university vs academic, OR = 0.08; 95%‐CI = 0.01‐0.65; P = .02) are also significant predictors for POS use. The second model did not identify any other significant patient characteristics. CONCLUSIONS: Future research should explore the role of institutional teaching status and whether associations with therapy after study inclusion are due to treatment effects – for example, less need following radiotherapy – or because access to POS is more difficult for those receiving radiotherapy.
format Online
Article
Text
id pubmed-7286449
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72864492020-06-11 Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis Breidenbach, Clara Roth, Rebecca Ansmann, Lena Wesselmann, Simone Dieng, Sebastian Carl, Ernst‐Günther Feick, Günter Oesterle, Alisa Bach, Peter Beyer, Burkhard Borowitz, Rainer Erdmann, Jörg Kunath, Frank Oostdam, Simba‐Joshua Tsaur, Igor Zengerling, Friedemann Kowalski, Christoph Cancer Med Clinical Cancer Research BACKGROUND: Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). METHODS: Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. RESULTS: Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of comorbidities (1‐2 vs 0, OR = 1.27; 95%‐CI = 1.00‐1.60; P=.048), disease staging (localized high‐risk vs localized intermediate risk, OR = 1.41; 95%‐CI = 1.14‐1.74; P < .001), receiving androgen deprivation therapy before study inclusion (OR = 0.19; 95%‐CI = 0.10‐0.34; P < .001), and hospital teaching status (university vs academic, OR = 0.09; 95%‐CI = 0.02‐0.55; P = .009). Model 2 additionally includes information on treatment after study inclusion and shows that after inclusion, patients who receive primary radiotherapy (OR = 0.05; 95%‐CI = 0.03‐0.10; P < .001) or undergo active surveillance/watchful waiting (OR = 0.06; 95%‐CI = 0.02‐0.15; P < .001) are less likely to utilize POS than patients who undergo radical prostatectomy. Disease staging (localized high‐risk vs localized intermediate risk, OR = 1.31; 95%‐CI = 1.05‐1.62; P = .02) and teaching status (university vs academic, OR = 0.08; 95%‐CI = 0.01‐0.65; P = .02) are also significant predictors for POS use. The second model did not identify any other significant patient characteristics. CONCLUSIONS: Future research should explore the role of institutional teaching status and whether associations with therapy after study inclusion are due to treatment effects – for example, less need following radiotherapy – or because access to POS is more difficult for those receiving radiotherapy. John Wiley and Sons Inc. 2020-03-31 /pmc/articles/PMC7286449/ /pubmed/32233081 http://dx.doi.org/10.1002/cam4.2999 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Breidenbach, Clara
Roth, Rebecca
Ansmann, Lena
Wesselmann, Simone
Dieng, Sebastian
Carl, Ernst‐Günther
Feick, Günter
Oesterle, Alisa
Bach, Peter
Beyer, Burkhard
Borowitz, Rainer
Erdmann, Jörg
Kunath, Frank
Oostdam, Simba‐Joshua
Tsaur, Igor
Zengerling, Friedemann
Kowalski, Christoph
Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title_full Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title_fullStr Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title_full_unstemmed Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title_short Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis
title_sort use of psycho‐oncological services by prostate cancer patients: a multilevel analysis
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286449/
https://www.ncbi.nlm.nih.gov/pubmed/32233081
http://dx.doi.org/10.1002/cam4.2999
work_keys_str_mv AT breidenbachclara useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT rothrebecca useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT ansmannlena useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT wesselmannsimone useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT diengsebastian useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT carlernstgunther useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT feickgunter useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT oesterlealisa useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT bachpeter useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT beyerburkhard useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT borowitzrainer useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT erdmannjorg useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT kunathfrank useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT oostdamsimbajoshua useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT tsaurigor useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT zengerlingfriedemann useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis
AT kowalskichristoph useofpsychooncologicalservicesbyprostatecancerpatientsamultilevelanalysis